VPC
MYGN icon

Vestal Point Capital’s Myriad Genetics MYGN Stock Holding History

Vestal Point Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7M Buy
5,735,000
+4,087,000
+248% +$18.6M 0.77% 34
2026
Q1 		$7.42M Buy
1,648,000
+425,000
+35% +$2.21M 0.21% 70
2025
Q4 		$7.52M Buy
1,223,000
+623,000
+104% +$4.52M 0.26% 54
2025
Q3 		$4.34M Buy
+600,000
New +$3.56M 0.2% 65

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestal Point Capital's MYGN Position: Q2 2026 in Review

Vestal Point Capital increased its Myriad Genetics (MYGN) stake by 248% in Q2 2026, buying an estimated $18.6M and bringing the position to 5,735,000 shares worth $32.7M. The position accounts for 0.77% of the portfolio, ranked #34.

Vestal Point Capital first reported a position in MYGN in Q3 2025 and has held it in 4 quarters since. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Vestal Point Capital held 5,735,000 shares of Myriad Genetics worth $32.7M as of Q2 2026.
  • Vestal Point Capital bought 4,087,000 Myriad Genetics shares in Q2 2026, an estimated $18.6M.
  • Myriad Genetics made up 0.77% of Vestal Point Capital's portfolio in Q2 2026, its #34 holding.
  • Vestal Point Capital first reported a position in Myriad Genetics in Q3 2025 and has held it in 4 quarters since.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.